Accordingly, improved antitumor efficacy has been observed with the combination of anti-PD-1 or anti-CTLA-4 in the context of ICOS co-stimulation (i.e., forced ICOSL expression and/or ICOS agonist antibody) in mouse syngeneic tumor models [5–7]. This evidence concerns the gene ICOS and neoplasm.